Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Healthcare Medical Devices
Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Therma Bright Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(742)
•••
Post by Smokey1958on Jul 11, 2021 11:50am
257 Views
Post# 33527681

Rapid COVID-19 tests could become workplace norm this fall

Rapid COVID-19 tests could become workplace norm this fallAnyone who thinks AcuVid is past its potential and usefulness doesn't read the news. The subject line is from an article in the Globe and Mail from two days ago.

https://www.theglobeandmail.com/business/article-rapid-covid-19-tests-could-become-workplace-norm-this-fall/

These other articles over the last week and a half that point to the same conclusion.

https://www.thephuketnews.com/health-authorities-agree-to-use-rapid-antigen-tests-to-detect-covid-19-80620.php

https://www.nih.gov/news-events/news-releases/nih-funded-screening-study-builds-case-frequent-covid-19-antigen-testing

https://news.err.ee/1608270771/rapid-antigen-tests-to-be-used-on-entry-to-estonia

https://www.irishtimes.com/news/politics/rapid-antigen-testing-may-be-part-of-indoor-dining-solution-says-coveney-1.4611438

Rapid antigen testing, even for those vaccinated, as for example in Ireland, is being considered as the only way to truly get back to some sense of normalcy. Imho with its CE mark the best place for AcuVid to get started is in Europe unless it can be fast tracked in countries in South America. For example while rates are falling for Brazil they still had more than 300,000 new cases and over 9000 deaths over the last week.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities